News
IMMP
2.250
+2.27%
0.050
Immutep: Report of foreign issuer
Press release · 16h ago
Immutep Advances Novel Autoimmune Therapy with Phase I Trial
TipRanks · 1d ago
Immutep Appoints Leading Research Institute To Conduct First-in-Human Phase I Study Of IMP761
Centre for Human Drug Research (CHDR) will conduct Phase I trial to evaluate IMP761, a first-in-class LAG-3 agonist antibody designed to restore balance to the immune system and address the underlying cause of autoimmune diseases. Trial expected to begin mid-CY2024.
Benzinga · 2d ago
IMMUTEP RECEIVES POSITIVE FEEDBACK FROM THE SPANISH MEDICINES AGENCY FOR UPCOMING TACTI-004 REGISTRATIONAL TRIAL IN METASTATIC NON-SMALL CELL LUNG CANCER
Reuters · 3d ago
Immutep Announced Tuesday, Positive Feedback From Spanish Medicines Agency For Upcoming TACTI-004 Registrational Trial In Metastatic Non-Small Cell Lung Cancer
Immutep is a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease. The company has received positive feedback from the Spanish Agency for Medicines and Health Products. The Company is developing a lung cancer trial for the treatment of lung cancer.
Benzinga · 3d ago
Weekly Report: what happened at IMMP last week (0408-0412)?
Weekly Report · 5d ago
Weekly Report: what happened at IMMP last week (0401-0405)?
Weekly Report · 04/08 10:18
Immutep Ltd (PRRUF) Gets a Buy from Bell Potter
TipRanks · 04/05 00:07
Weekly Report: what happened at IMMP last week (0325-0329)?
Weekly Report · 04/01 10:17
Weekly Report: what happened at IMMP last week (0318-0322)?
Weekly Report · 03/25 10:19
Weekly Report: what happened at IMMP last week (0311-0315)?
Weekly Report · 03/18 10:17
Weekly Report: what happened at IMMP last week (0304-0308)?
Weekly Report · 03/11 10:16
Analyst Issues Buy Rating on Immutep Stock Amid Promising Efti Drug Trial Results
TipRanks · 03/07 05:00
Immutep: Report of foreign issuer
Press release · 03/06 12:00
Cancer Focused Immutep's Stock Soars On Tuesday - Here's Why
Immutep Limited announces safety and initial efficacy data from the first ever 90mg dosing of eftilagimod alpha in combination with weekly paclitaxel. The drug is being tested in a Phase 2/3 trial of breast cancer patients. No serious adverse events were reported.
Benzinga · 03/05 20:57
Immutep Announces First Clinical Data From 90mg Dosing Of Efti
Data from the safety lead-in of the AIPAC-003 trial shows 90mg efti in combination with paclitaxel is safe and well tolerated. Encouraging initial efficacy in six metastatic breast cancer patients, demonstrated by a 50% overall response rate, and a 100% disease control rate.
Benzinga · 03/05 13:12
Weekly Report: what happened at IMMP last week (0226-0301)?
Weekly Report · 03/04 10:18
Weekly Report: what happened at IMMP last week (0219-0223)?
Weekly Report · 02/26 10:25
Weekly Report: what happened at IMMP last week (0212-0216)?
Weekly Report · 02/19 10:26
Weekly Report: what happened at IMMP last week (0205-0209)?
Weekly Report · 02/12 10:20
More
Webull provides a variety of real-time IMMP stock news. You can receive the latest news about Immutep through multiple platforms. This information may help you make smarter investment decisions.
About IMMP
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.